Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned an average rating of “Buy” from the eight research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $41.25.

A number of analysts recently issued reports on ACRS shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. Guggenheim reaffirmed a “buy” rating and issued a $40.00 target price on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. BidaskClub raised Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $39.00 target price on shares of Aclaris Therapeutics in a research report on Friday, September 8th.

ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics, Inc. (ACRS) Receives $41.25 Average Target Price from Analysts” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/16/aclaris-therapeutics-inc-acrs-receives-41-25-average-target-price-from-analysts.html.

In other Aclaris Therapeutics news, Director Andrew N. Schiff purchased 108,601 shares of the stock in a transaction on Wednesday, August 16th. The shares were purchased at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. increased its position in Aclaris Therapeutics by 55.4% during the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after buying an additional 697,104 shares during the last quarter. Rosenblum Silverman Sutton S F Inc. CA increased its position in Aclaris Therapeutics by 17.3% during the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after buying an additional 5,650 shares during the last quarter. American International Group Inc. increased its position in Aclaris Therapeutics by 31.3% during the first quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock worth $203,000 after buying an additional 1,623 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Aclaris Therapeutics by 6.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 43,961 shares of the biotechnology company’s stock worth $1,311,000 after buying an additional 2,736 shares during the last quarter. Finally, EcoR1 Capital LLC increased its position in Aclaris Therapeutics by 62.6% during the first quarter. EcoR1 Capital LLC now owns 673,100 shares of the biotechnology company’s stock worth $20,072,000 after buying an additional 259,100 shares during the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Aclaris Therapeutics (NASDAQ ACRS) remained flat at $26.14 on Wednesday. 83,417 shares of the stock traded hands. The company’s market cap is $698.88 million. Aclaris Therapeutics has a 1-year low of $20.15 and a 1-year high of $33.25. The firm’s 50 day moving average is $26.20 and its 200 day moving average is $27.02.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.12. Equities analysts forecast that Aclaris Therapeutics will post ($3.10) earnings per share for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.